Subsequent administration of the ARB losartan (100 mg daily for 6 months) compared to a control CKD group on amlodipine found significant reductions in adiponectin (P < 0.01) accompanied by reductions in HbA1c (P < 0.01), fasting insulin (P < 0.01) and HOMA-IR, measure of insulin resistance (P < 0.01). Here, INS is linked to chronic kidney disease.